FDA Approves Nivolumab and Ipilimumab Combination for Advanced Kidney Cancer

FDA has approved the combination of two immunotherapy drugs, nivolumab (Opdivo) and ipilimumab (Yervoy), as an initial treatment for some patients with advanced kidney cancer. Learn how this approval will affect patient care.

Cancer Currents: An NCI Cancer Research Blog